---
title: "Feiolix (feijoa powder) supplementation in adults with overweight prediabetes: randomized trial ef"
id: "medrxiv-14-effect-of-daily-consumption-of-whole-fruit-feijoa-powder-feiolix-on-metabolic"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-14-effect-of-daily-consumption-of-whole-fruit-feijoa-powder-feiolix-on-metabolic"
content_type: "clinical_feed_article"
specialty: "Endocrinology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.09.13.26362958v1?rss=1"
published_at: "2026-09-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Feiolix (feijoa powder) supplementation in adults with overweight prediabetes: randomized trial ef
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-14-effect-of-daily-consumption-of-whole-fruit-feijoa-powder-feiolix-on-metabolic
- **Specialty:** [Endocrinology](https://medichelpline.com/clinical-feed/endocrinology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.09.13.26362958v1?rss=1)
- **Published At:** 2026-09-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This randomized, placebo-controlled 12-week trial evaluated daily supplementation with whole-fruit **feijoa** powder (Feiolix) in adults aged 21–65 with **prediabetes** (HbA1c 5.7–6.4%) and overweight (BMI 25.0–29.9 kg/m2). 39 participants were randomized (13 per arm); one withdrawal occurred in the low-dose group. - Interventions were Feiolix low dose (300 mg/day), Feiolix high dose (1,150 mg/day), and placebo (maltodextrin). Anthropometry was measured monthly; fasting and postprandial blood samples were collected at baseline and week 12. - Primary and secondary outcomes included **HbA1c**, **GLP‑1**, fasting plasma glucose, insulin, HOMA‑IR, lipid markers (total cholesterol, LDL, triglycerides), body weight and BMI. Analyses used ANCOVA with baseline covariates. - At 12 weeks, **HbA1c** fell by 0.5% in the high‑dose group and 0.4% in the low‑dose group; both reductions were statistically greater than placebo (p < 0.05). - Feiolix supplementation significantly lowered fasting glucose, insulin, **HOMA‑IR**, total cholesterol and **LDL‑cholesterol** versus placebo. The high dose attenuated the triglyceride increase observed in placebo and produced significant reductions in body weight and **BMI** by month 2 compared with placebo. - No between‑group differences in **GLP‑1** were observed. No treatment‑related adverse events were reported. - The product is a whole‑fruit feijoa powder containing abscisic acid, polyphenols and dietary fiber; proposed mechanisms include complementary metabolic pathways but mechanistic biomarkers beyond measured endpoints were not reported. - Trial registration: CTRI/2025/08/093439. Ethics approval: Ethicare Ethics Committee, Mumbai Suburban, CDSCO registration ECR/224/Indt/MH/2015/RR-21. Competing interests: authors include employees of the manufacturer and a company with potential royalty interest; these were declared. - Data availability: datasets available from corresponding author on reasonable request. As a medRxiv preprint, this study has not undergone peer review and should not be used to guide clinical practice.
## Clinical Analysis & Structured Key Points
Effect of daily consumption of whole fruit feijoa powder (Feiolix) on metabolic profile: A Randomised Controlled Trial | medRxiv Skip to main content Effect of daily consumption of whole fruit feijoa powder (Feiolix) on metabolic profile: A Randomised Controlled Trial View ORCID Profile Aahana Shrestha , Ashish Sarvate , Dilip Mehta , Neeta Nargundhar , Deepak Deshmukh , Chhaya Godse doi: https://doi.org/10.64898/2026.09.13.26362958 Aahana Shrestha 1 Anagenix IP Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site ORCID record for Aahana Shrestha For correspondence: aahana.shrestha{at}anagenix.com Ashish Sarvate 2 Sarwate's Diabetes and Foot Care Centre; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Dilip Mehta 3 Viridis BioPharma Pvt Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Neeta Nargundhar 4 Biosphere Clinical Research Pvt. Ltd Find this author on Google Scholar Find this author on PubMed Search for this author on this site Deepak Deshmukh 4 Biosphere Clinical Research Pvt. Ltd Find this author on Google Scholar Find this author on PubMed Search for this author on this site Chhaya Godse 3 Viridis BioPharma Pvt Ltd; Find this author on Google Scholar Find this author on PubMed Search for this author on this site Abstract Info/History Metrics Data/Code Preview PDF Abstract Background: Prediabetes is an intermediate state of increased glucose concentrations above the normal range but below the diagnostic threshold for type 2 diabetes (T2D). Adults with overweight and prediabetes are at increased risk of progression to T2D and metabolic imbalance. Feiolix -a whole–fruit feijoa powder rich in abscisic acid, polyphenols and dietary fibre which may support metabolic health with complementary pathways. Objective: To evaluate the effects of low and high–dose Feiolix compared with placebo, on HbA1C, glucagon like peptide (GLP–1) and other metabolic parameters. Methods: Adults aged 21–65 years with prediabetes i.e. glycosylated hemoglobulin (HbA1c) 5.7–6.4% and overweight with body mass index (BMI)- 25.0–29.9 kg/m2 were randomised to receive Feiolix–LD (300 mg/day) or Feiolix–HD (1,150 mg/day), or placebo (maltodextrin) for 12 weeks. Anthropometric measurements were obtained monthly, and fasting blood samples were collected at baseline and 12 weeks post intervention. Postprandial blood samples were collected at baseline and 12 weeks. Outcomes included HbA1c, GLP–1, fasting plasma glucose, insulin resistance lipid markers, body weight and BMI. Analyses were conducted using ANCOVA model with baseline values as covariates. Result: Of 41 individuals screened, 39 were randomised (13 per group); one participant withdrew from the Feiolix–LD. At week 12, HbA1c decreased by 0.5% in the Feiolix–HD and by 0.4% in the Feiolix–LD, with both reductions significantly greater than placebo (p < 0.05); Compared with placebo, Feiolix supplementation significantly lowered fasting glucose, insulin, HOMA–IR, total cholesterol and LDL–cholesterol. The Feiolix–HD significantly attenuated the increase in triglycerides observed in the placebo group and was associated with significant reductions in body weight and BMI versus placebo by month 2. However, no change in GLP–1 was observed between the treatments. No treatment–related adverse events were reported. Conclusion: This study supports the potential of Feiolix supplementation to improve metabolic health, including glycemic and lipid outcomes, with additional benefits for body weight and BMI at the higher dose. This study supports the potential of Feiolix supplementation to improve metabolic health, including glycemic and lipid outcomes, with additional benefits for body weight and BMI at the higher dose Competing Interest Statement A.S is employee of Anagenix Ltd, which manufactures and sells Feiolix powder, at the time of the study. C.G. and D.M have been employed by Viridis Biosciences, which stands to receive royalties from any sale of Feiolix, during the study and manuscript preparation. Clinical Trial CTRI/2025/08/093439 Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study has been approved by Ethicare Ethics Committee, Mumbai Suburban Maharashtra - 400083 India with CDSCO registration no: ECR/224/Indt/MH/2015/RR-21 I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes Data Availability The datasets generated during and/or analysed during the current study are available from the corresponding author on reasonable request Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license . Back to top Previous Next Posted September 22, 2026. Download PDF Data/Code Email Thank you for your interest in spreading the word about medRxiv. NOTE: Your email address is requested solely to identify you as the sender of this article. Your Email * Your Name * Send To * Enter multiple addresses on separate lines or separate them with commas. You are going to email the following Effect of daily consumption of whole fruit feijoa powder (Feiolix) on metabolic profile: A Randomised Controlled Trial Message Subject (Your Name) has forwarded a page to you from medRxiv Message Body (Your Name) thought you would like to see this page from the medRxiv website. Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. Share Effect of daily consumption of whole fruit feijoa powder (Feiolix) on metabolic profile: A Randomised Controlled Trial Aahana Shrestha , Ashish Sarvate , Dilip Mehta , Neeta Nargundhar , Deepak Deshmukh , Chhaya Godse medRxiv 2026.09.13.26362958; doi: https://doi.org/10.64898/2026.09.13.26362958 Share This Article: Copy Citation Tools Effect of daily consumption of whole fruit feijoa powder (Feiolix) on metabolic profile: A Randomised Controlled Trial Aahana Shrestha , Ashish Sarvate , Dilip Mehta , Neeta Nargundhar , Deepak Deshmukh , Chhaya Godse medRxiv 2026.09.13.26362958; doi: https://doi.org/10.64898/2026.09.13.26362958 Citation Manager Formats BibTeX Bookends EasyBib EndNote (tagged) EndNote 8 (xml) Medlars Mendeley Papers RefWorks Tagged Ref Manager RIS Zotero Tweet Widget Facebook Like Google Plus One Subject Area Nutrition Subject Areas All Articles Addiction Medicine (619) Allergy and Immunology (903) Anesthesia (335) Cardiovascular Medicine (4834) Dentistry and Oral Medicine (479) Dermatology (419) Emergency Medicine (651) Endocrinology (including Diabetes Mellitus and Metabolic Disease) (1633) Epidemiology (15981) Forensic Medicine (33) Gastroenterology (1206) Genetic and Genomic Medicine (7068) Geriatric Medicine (734) Health Economics (1067) Health Informatics (5067) Health Policy (1438) Health Systems and Quality Improvement (1776) Hematology (587) HIV/AIDS (1347) Infectious Diseases (except HIV/AIDS) (16310) Intensive Care and Critical Care Medicine (1177) Medical Education (672) Medical Ethics (155) Nephrology (727) Neurology (7305) Nursing (370) Nutrition (1086) Obstetrics and Gynecology (1244) Occupational and Environmental Health (1007) Oncology (3622) Ophthalmology (1057) Orthopedics (398) Otolaryngology (458) Pain Medicine (476) Palliative Medicine (140) Pathology (709) Pediatrics (1805) Pharmacology and Therapeutics (739) Primary Care Research (769) Psychiatry and Clinical Psychology (5923) Public and Global Health (9776) Radiology and Imaging (2435) Rehabilitation Medicine and Physical Therapy (1456) Respiratory Medicine (1250) Rheumatology (643) Sexual and Reproductive Health (773) Sports Medicine (582) Surgery (783) Toxicology (107) Transplantation (306) Urology (293)
## Related Clinical Research

- [Machine learning prediction models for hypoglycemia in Chinese patients with diabetes: systematic](https://medichelpline.com/clinical-feed/plos-one-2-performance-of-machine-learning-based-prediction-models-for-hypoglycemia-in.md)
- [Optimised carbohydrate diet with increased resistant starch to improve metabolic health in adults](https://medichelpline.com/clinical-feed/bmj-open-14-optimised-carbohydrate-dietary-intervention-for-improving-metabolic-health-in.md)
- [Antidiabetic regimens and risk of cognitive disorders in type 2 diabetes: large retrospective coho](https://medichelpline.com/clinical-feed/plos-one-23-antidiabetic-medications-and-risk-of-cognitive-disorders-in-type-2-diabetes-a.md)
- [NIH awards $4.6M to multi-university team to model hormones and improve women's health](https://medichelpline.com/clinical-feed/endocrine-news-0-nih-awards-multi-university-team-over-4m-to-improve-women-s-health.md)
- [Thyroid Function and MAFLD in Type 2 Diabetes: Case-Control Study of FT3 and TSH Associations](https://medichelpline.com/clinical-feed/pubmed-42664128.md) (DOI: 10.7417/CT.2026.2108)

## Navigation
- [← Back to Endocrinology Feed](https://medichelpline.com/clinical-feed/endocrinology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.